AI Citation Summary
AI Summary
In 2001, the former Ministry of Health promulgated the "Human Assisted Reproductive Technology Management Measures," marking the beginning of standardized management of assisted reproductive technology in China. Over the past two decades, these measures and supporting regulations have formed the core legal framework for the clinical application of domestic assisted reproductive technology. In 2023, the State Council issued the "Regulations on the Management of Human Assisted Reproductive Technology (Draft for Comments)," aiming to further upgrade the legal level and regulatory intensity. The following content is based on the current effective legal system, combined with the new directions of the draft, to provide reference for patients and practitioners.
What the Regulations Govern
China's Assisted Reproductive Technology Management Regulations (currently based on the "Human Assisted Reproductive Technology Management Measures," collectively referred to as the "Regulations") are administrative regulations governing medical institutions in carrying out assisted reproductive technology. They clearly answer three core questions:
- Who can do it — Medical institutions must have the corresponding qualifications and obtain an approval certificate before carrying out artificial insemination, in vitro fertilization-embryo transfer, and related technologies.
- How to do it — Must comply with technical specifications, ethical principles, and quality control standards, including specific operational requirements such as ovulation induction protocols, embryo culture, and limits on the number of embryos transferred.
- What cannot be done — Explicitly prohibits surrogacy, sex selection without medical indication, illegal trading of gametes and embryos, and unauthorized embryo culture beyond 14 days.
The regulations apply to all medical institutions carrying out human assisted reproductive technology, including general hospital reproductive centers, specialized hospitals, and human sperm banks. They do not apply to basic research in scientific research institutions (but research involving gametes and embryos still requires ethical review).
Why Such Strict Regulations Are Necessary
Assisted reproductive technology involves complex medical and ethical issues such as gametes, embryos, genetic information, and intergenerational health. Lax management could lead to the following risks:
- Medical safety risks: Ovulation induction complications, multiple pregnancies, ovarian hyperstimulation syndrome, etc., directly threaten patient health.
- Ethical risks: Commercialization of gametes and embryos, legal disputes arising from surrogacy, improper disposal of embryos, and other ethical controversies.
- Genetic risks: Unclear sources of genetic material or non-standard screening may lead to the transmission of genetic diseases to offspring.
- Social risks: Population structure imbalance due to sex selection, infringement on the rights of women and children through illegal surrogacy.
Through mechanisms such as access approval, annual inspections, unannounced inspections, and ethical supervision, the regulations keep the above risks within an acceptable range. The 2023 draft further strengthens penalties for violations, reflecting the legislative direction of "strict management."
Actual Process for Institutions Applying for Qualifications
For a medical institution to legally carry out assisted reproductive technology, it must go through the following approval process:
- Institution self-assessment and preparation: According to the requirements of the "Human Assisted Reproductive Technology Standards," equip with facilities, equipment, personnel (including reproductive medicine clinicians, embryologists, nursing staff, etc.), establish a quality control system and an ethics committee.
- Preliminary review by provincial health administrative department: Submit application materials, including practice license, personnel qualification certificates, facility layout plan, equipment list, technical plan, ethics committee charter, etc.
- National expert review: An expert group organized by the Ministry of Health (now the National Health Commission) conducts an on-site review, including clinical technical capability, laboratory conditions, and ethical review capability. The review result is classified as "qualified," "qualified after rectification," or "unqualified."
- Issuance of approval certificate: After passing the review, the National Health Commission issues the "Human Assisted Reproductive Technology Approval Certificate," specifying the permitted technology types (e.g., artificial insemination by husband, artificial insemination by donor, in vitro fertilization-embryo transfer, intracytoplasmic sperm injection, preimplantation genetic diagnosis, etc.).
- Regular inspection: After obtaining the certificate, undergo an inspection every 2 years. If the inspection is unqualified, rectification is required within a time limit; if still unqualified after rectification, the certificate is revoked.
Doctor's perspective: The most common problems encountered by the director of a reproductive medicine center during the preparation phase are "incomplete personnel梯队" and "non-standard ethical review records." Review experts particularly value the actual operational capability and quality indicators of the embryo laboratory, rather than just hardware configuration. It is recommended that institutions undergo a 3-6 month study visit at an already approved center before formally submitting an application.
Most Common Pitfalls
According to practitioner observations, medical institutions most easily overlook the following aspects during compliance:
- Formalistic ethical review: The ethics committee has a charter and meeting minutes, but actual review lacks thorough discussion of specific cases, especially those involving donor sperm, donor eggs, and PGT. The regulations require that each special case be independently reviewed by the ethics committee.
- Incomplete informed consent forms: Some institutions' informed consent forms do not cover key terms such as embryo disposal, multifetal pregnancy reduction, and the number of embryos to be transferred, or the signing process is not standardized (e.g., not signed separately, no copy retained).
- Exceeding the limit on the number of embryos transferred: According to the "Human Assisted Reproductive Technology Standards," there is a clear limit on the number of embryos transferred (usually no more than 2, and no more than 3 in special circumstances). Some institutions transfer more embryos to increase success rates, which is a violation.
- Non-compliant gamete sources: When using donor sperm or eggs, they must come from approved human sperm banks or egg banks (currently, egg banks are not fully established in China; egg sources are limited to voluntary donations from patients receiving assisted reproductive treatment). Private purchases or directed donations do not comply with regulations.
- Failure to undergo timely inspection: The approval certificate is valid for 2 years, and an inspection application must be submitted 6 months before expiration. Some institutions continue to perform technologies after the certificate expires due to delayed preparation, which is deemed illegal medical practice.
Special reminder: When choosing an institution, patients can request to see the original "Human Assisted Reproductive Technology Approval Certificate" and verify whether the technology types listed on the certificate include the items they need. They can also check the "List of Medical Institutions Approved to Carry Out Assisted Reproductive Technology" and "Inspection Results" published on the official website of the National Health Commission.
Special Situation Handling and Compliance Boundaries
Some special clinical situations need to be judged in conjunction with specific provisions of the regulations:
- Artificial insemination by donor (AID): Must use frozen semen provided by an approved human sperm bank, and the source information of the semen must be traceable. The regulations prohibit the use of fresh donor semen and direct donations between individuals.
- In vitro fertilization with donor eggs: Currently, domestic sources of donor eggs are limited to eggs voluntarily donated by patients undergoing assisted reproductive treatment, and donors must complete their own treatment cycle before donating. Recruiting egg donors for commercial purposes and buying/selling eggs are prohibited.
- Preimplantation genetic diagnosis (PGT): Only applicable to couples with a clear risk of genetic diseases or chromosomal abnormalities, requires review by the ethics committee, and cannot be used for sex selection without medical need.
- Embryo freezing and disposal: When signing the informed consent form, patients must specify the embryo freezing period, renewal method, and disposal method after abandonment (e.g., destruction, use for research, or donation). Medical institutions cannot dispose of embryos without the patient's authorization.
- Multifetal pregnancy reduction: The regulations allow reduction surgery in cases of triplet or higher-order pregnancies, but the risks must be fully explained, and written consent from the patient must be obtained. The reduction surgery itself is a medical technical operation and is not separately included in the scope of assisted reproductive technology management.
Services promoted by overseas institutions in China, such as "guaranteed success," "sex selection," and "surrogacy," are all violations of Chinese regulations. Patients should be wary of such promotions to avoid legal disputes.
Frequently Asked Questions
| Question | Key Points |
|---|---|
| Can all hospitals perform IVF? | No. Only medical institutions that have obtained the "Human Assisted Reproductive Technology Approval Certificate" can perform it. As of 2024, there are approximately 600 approved institutions nationwide; the specific list can be found on the official website of the National Health Commission. |
| Is a marriage certificate required for IVF? | Yes. The regulations require couples receiving assisted reproductive technology to provide a marriage certificate, ID card, and birth certificate (in line with family planning policies). Unmarried individuals or those not meeting family planning policies cannot legally receive assisted reproductive technology in China. |
| Can the sex of the baby be chosen for IVF? | No. The regulations explicitly prohibit sex selection without medical indication. Only when couples have a risk of sex-related genetic diseases (such as hemophilia) can embryo sex be selected through PGT technology, and it requires approval from the ethics committee. |
| Is surrogacy legal in China? | No. The regulations explicitly prohibit any form of surrogacy. Medical institutions cannot perform surrogacy techniques, and patients cannot seek surrogacy services domestically. Overseas surrogacy carries high legal risks, and individuals must bear the consequences themselves. |
| What tests are needed before IVF? | Women need to complete gynecological examination, endocrine examination, AMH, infectious disease screening, chromosome karyotype analysis, etc.; men need to complete semen analysis, infectious disease screening, chromosome karyotype analysis, etc. Specific items are carried out according to the "Human Assisted Reproductive Technology Standards." |
| Can embryos be frozen indefinitely? | No. Medical institutions usually agree on a freezing period with patients (generally 5-10 years), after which renewal or signing of a disposal consent form is required. The regulations require medical institutions to regularly check the status of frozen embryos to avoid long-term retention of unclaimed embryos. |
Practitioner Observation: Actual Changes in Regulation Enforcement
Having worked in the field of assisted reproduction for over a decade, I have observed several clear trends in the enforcement of the regulations:
- Gradually increasing approval thresholds: In the early days, some institutions could be approved after meeting hardware requirements. In recent years, reviews have placed more emphasis on clinical data, quality indicators, and the substantive effectiveness of ethical reviews. New institutions typically take 3-5 years from preparation to approval.
- Increasingly strict inspections: The proportion of unannounced inspections (on-site inspections without prior notice) has increased, focusing on key aspects such as the number of embryos transferred, donor sperm sources, and embryo disposal records. In a 2023 provincial inspection, two institutions had their technical qualifications suspended due to incomplete transfer records.
- Enhanced patient rights awareness: Cases involving informed consent disputes and embryo disposal controversies are increasing year by year. The regulations provide patients with a clear basis for their rights, requiring medical institutions to be more standardized in communication and document signing.
- Regulatory lag in the application of new technologies: New clinical applications such as mitochondrial replacement technology, assisted hatching, and embryo culture medium additives currently lack clear regulatory details. Institutions must apply separately to the health administrative department and pass ethical review before carrying them out.
Recommendation: When choosing an institution, patients should prioritize reproductive centers that have been approved by the National Health Commission and have continuously passed inspections. Also, pay attention to whether the institution proactively discloses quality indicators such as annual inspection results, embryo transfer success rates, and multiple pregnancy rates. Compliance is a prerequisite for safety, not just "having a certificate."
⏳ Reminder for Special Populations
For patients aged ≥35 years, with diminished ovarian reserve (AMH < 1.1 ng/mL), a history of recurrent miscarriage, or previous assisted reproductive failure, it is recommended to fully understand the institution's embryo culture level and genetic counseling capabilities before starting treatment. Although the regulations do not directly limit the patient's age and ovarian condition, older individuals and those with low reserve have higher requirements for technical quality and should choose a center with corresponding experience.
Suggestions for Next Steps: If you have decided to undergo assisted reproductive treatment in China, the first step is to verify whether the chosen institution has a valid "Human Assisted Reproductive Technology Approval Certificate" and confirm that its inspection status is "qualified." The second step is to have an initial consultation with the reproductive medicine team to understand their strategy for controlling the number of embryos transferred, multiple pregnancy rates, and complication management capabilities. The third step is to sign a standardized informed consent form, paying special attention to the terms regarding embryo freezing, renewal, and disposal.
Risk Warning: Assisted reproductive technology carries medical risks such as ovarian hyperstimulation syndrome, multiple pregnancy, miscarriage, and ectopic pregnancy. The regulations cannot eliminate these risks but control them within a reasonable range through standardized management. Patients should fully understand their own health conditions and work with their doctors to develop an individualized treatment plan.
Comments (0)